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ABSTRACT 
Purpose The purpose was to develop a mechanistic mathematical model for predicting the 
pharmacokinetics of topically applied solutes penetrating through the skin and into the blood circulation. 
The model could be used to support the design of transdermal drug delivery systems and skin care 
products, and risk assessment of occupational or consumer exposure. 
Methods A recently reported skin penetration model [Pharm Res 32 (2015) 1779] was integrated with 
the kinetic equations for dermis-to-capillary transport and systemic circulation. All model parameters 
were determined separately from the molecular, microscopic and physiological bases, without fitting to 
the in vivo data to be predicted. Published clinical studies of nicotine were used for model 
demonstration.  
Results The predicted plasma kinetics is in good agreement with observed clinical data. The simulated 
two-dimensional concentration profile in the stratum corneum vividly illustrates the local sub-cellular 
disposition kinetics, including tortuous lipid pathway for diffusion and the “reservoir” effect of the 
corneocytes. 
Conclusions A mechanistic model for predicting transdermal and systemic kinetics was developed and 
demonstrated with published clinical data. The integrated mechanistic approach has significantly 
extended the applicability of a recently reported microscopic skin penetration model by providing 
prediction of solute concentration in the blood.  
 
 
KEY WORDS  
Diffusion; Disposition; Percutaneous absorption; Physiologically-based pharmacokinetic modelling; 
Toxicokinetics.  
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ABBREVIATIONS 
3Rs Replacement, Refinement and Reduction 
CVODE C-language Variable-coefficients ODE solver 
MW Molecular Weight 
ODE Ordinary Differential Equation 
PDE Partial Differential Equation 
QSPR Quantitative Structure-Property Relationship 
SUNDIALS SUite of Nonlinear and DIfferential/ALgebraic equation Solvers 
SWIG Simplified Wrapper and Interface Generator 
 
INTRODUCTION 
Transdermal permeation of chemicals is an important topic in a range of applications, such as 
transdermal delivery of drugs, design of skin care and cosmetic products, and safety assurance and risk 
assessment of exposure to hazardous chemicals. Due to its effective barrier properties, skin is of 
significant interest to controlled release of pharmaceutical and other products (1, 2). In the past, 
research in this field largely relied on in vivo, ex vivo and in vitro tests (especially in early phase 
development), and clinical studies with human volunteers (typically in late phase trials). This empirical 
approach is time consuming and expensive. In recent years, the research paradigm has undergone a 
significant change towards more mechanistic and holistic understanding of various transdermal 
permeation pathways, including the role of the physico-chemical properties of the solute of interest and 
its interaction with skin. Within this context, mathematical modelling, also referred to as in silico 
approach, has emerged as an important technology to improve fundamental understanding of the 
transdermal permeation kinetics. This in silico approach is also an important approach to the 
replacement, refinement and reduction of animal tests in research (the 3Rs). 
In the literature, various modelling studies on transdermal permeation have been reported. A 
frequently cited approach is the empirical quantitative structure-property relationship (QSPR) models, 
which intend to predict the steady-state permeability coefficient based on experimental results of 
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percutaneous absorption (3, 4). Extension from steady-state to kinetic modelling has been achieved by 
the compartmental approach, which treats the skin layers as different compartments each having 
uniform concentration, e.g. (5, 6) and other studies reviewed by Anissimov et al. (7). A major limitation 
of the compartment model is that the model parameters often need to be fitted to experimental data, and 
thus the extrapolation capability is limited. More recently, significant attention has been given to the 
diffusion-based models that use the Fick’s second law of diffusion to describe time-dependant solute 
diffusion across skin layers. Early diffusion-based models ignored the heterogeneous structure of the 
stratum corneum and described the transdermal permeation as diffusion in homogeneous media (8, 9); 
however the model parameters also needed to be fitted to experimental data in order to make 
satisfactory predictions. Since the heterogeneous “brick-and-mortar” structure of the stratum corneum 
was introduced to in silico modelling, the main challenge has been to obtain the transport and 
disposition properties (diffusion and partition coefficients). Some models chose to obtain these 
properties by data-fitting (10), limiting the applicability of the model. Wang et al. (11, 12) reported a 
more predictive two-dimensional model, in which the diffusion and partition coefficients were obtained 
from fundamental principles, and only the trans-bilayer mass transfer coefficient was fitted to deduce a 
correlation with the molecular weight. A similar two-dimensional approach was taken by Lian and co-
workers (13, 14), where data-fitting was only used to derive a correlation for calculating the diffusion 
coefficient in corneocytes, and the prediction accuracy was significantly improved when compared with 
the Wang’s model in (11, 12). With consideration of the two-dimensional microscopic skin structure, 
both models (11, 12, 13, 14) demonstrated the importance of the trans-cellular diffusion pathway 
through the stratum corneum. In a later study, Lian and co-workers extended their model to include 
viable epidermis and dermis whilst maintaining the predictive capability (15). Some excellent review 
articles have been published to summarise the recent progress in this area; see e.g. (7, 16, 17). 
The majority of the transdermal permeation models developed, especially those incorporating more 
realistic heterogeneous skin physiology (11, 12, 13, 15), were intended to predict the absorption kinetics 
in the skin only. When the chemical reaches the dermis, it is cleared from the skin through both 
diffusion into deeper tissues and convention by the capillary blood vessels. Although the dermis 
clearance pathways have been modelled (18, 19, 20, 21), the focus was still on improving the modelling 
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accuracy within skin. The kinetics in systemic circulation has not been considered in these studies. 
Systemic circulation was included in many compartment-based pharmacokinetic models (5, 6, 22), but 
they have limited predictive capability due to the lack of sufficient microscopic details in skin. 
Therefore, there is a need to connect the microscopic skin penetration models with systemic circulation 
kinetics, so that prediction capability can be extended to the concentration profile in circulation. This 
capability is important because the plasma concentration profile is one of the primary parameters from 
the efficacy and safety perspectives in many applications. In addition, by validating the model against in 
vivo plasma data, one can also infer detailed kinetic and bioavailability information in various skin 
layers from the model, which are not normally available in clinical studies. 
Against this background, this study aims to integrate our recently reported skin penetration model 
with systemic circulation kinetics. Following the previous studies (13, 15), the brick-and-mortar model 
is used to represent the heterogeneous structure of the stratum corneum, while the viable epidermis and 
dermis are modelled as homogenised material with properties related to the main compositions of 
cellular lipid, protein and water. The transport of chemicals within skin is governed by diffusion 
equations, and that into capillary blood is modelled by using the assumption of equilibrium between 
dermis and blood, following the method in (5). Importantly, the partition and diffusion properties are 
calculated by relating to the fundamental physico-chemical properties of solutes, rather than fitting to 
the data to be predicted. The physiology in skin and blood circulation (e.g. depth of skin layers, 
capillary blood flow rate, whole body blood volume, etc.) is also used. The model has been 
implemented in C++, which allowed fast computation using a much finer grid scheme in stratum 
corneum than reported previously (13, 15). It should be noted that the coarse grids previously used (13, 
15) were deemed numerically sufficient for predicting one-dimensional pharmacokinetics, as further 
refinement of the grids did not improve the resolution. However, for the purpose of simulating detailed 
two-dimensional local disposition, higher resolution is needed and this is the motivation of using finer 
grids in the present study. The model is applied to predict the published data from clinical studies of 
transdermal nicotine patches (23, 44). The prediction is in good agreement with the published data, 
showing excellent prediction capability achieved with the integrated model of both transdermal 
permeation kinetics and systemic circulation kinetics. In addition, the simulated detailed two-
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dimensional concentration profile of nicotine in the stratum corneum vividly illustrates the tortuous 
lipid pathway for diffusion (the “fingering” effect) and the “reservoir” effect of the corneocytes. 
 
MATERIAL AND METHODS 
This section describes the modelling method in general, followed by the particular details of reported 
clinical studies of nicotine that were used for the initial validation and demonstration of the model. 
 
The Mathematical Model 
Figure 1 illustrates the modelling framework including a single homogenous vehicle layer, a two-
dimensional heterogeneous brick-and-mortar structure of the stratum corneum, one-dimensional 
(vertical diffusion) schemes for the viable epidermis and dermis, the coupling of solute diffusion in 
dermis with transport into the blood capillaries, and the solute clearance in the circulation. The 
simulation scheme for stratum corneum, viable epidermis and dermis is the same as the previous study 
(15).  
 (Figure 1 about here) 
 
The overall simulation approach 
The simulation is based on solving the diffusion equation that describes the transport of solute. The 
time- and space-dependent partial differential equation (PDE) of diffusion is solved by the method of 
lines. More specifically, the simulation domain is discretised into grids, which allow for the conversion 
of the PDE into a large number of ordinary differential equations (ODEs). The grid scheme for the 
vehicle (one grid), the viable epidermis (ten vertically and equally spaced grids) and the dermis (ten 
vertically and equally spaced grids) is the same as in the previous study (15). However, to allow for 
detailed simulation of the stratum corneum, the main penetration barrier, much finer grids were used: in 
the vertical direction, two grids were used for the lipid bi-layer and four for the corneocytes; in the 
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lateral direction, two grids were used for the inter-cellular lipid and 20 for the corneocytes. In total, this 
gives rise to 3,189 grids in the skin, plus one compartment for the blood (i.e. 3,190 ODEs). 
The flux due to diffusion between any two neighbouring grids, either in the vertical or lateral 
direction, in the simulation domain is described by the following mass transfer equation: 
 
    
 
  
  
 
     
  
           (1) 
where     is the rate of mass transfer (kg s
-1
) from grid i to grid j, A is the interfacial area between the 
two grids,    and    are the corresponding diffusion lengths,    and    are the diffusivity of the 
corresponding grids,     is the solute partition coefficient between grid i and j, and    and     are the 
concentration in grid i and j, respectively. Since water is the reference used for partition coefficients, 
    can be calculated as the ratio of     (partition coefficient from grid i to water) to     (partition 
coefficient from grid j to water), which depend on the type of material of the grid and the calculation 
will be detailed in Section 2.1.2. 
Building on the mass transfer rate described in eq. (1), the law of mass conservation requires that 
the concentration in each simulation grid in the vehicle, stratum corneum and viable epidermis follows 
the differential equation: 
   
   
  
  ∑   
 
 (2) 
where    is the volume of grid i, t is time, and the summation is for all the grids that are neighbours of 
grid i. 
In addition to diffusion, convection needs to be considered when modelling the transport between 
dermis and capillaries due to the blood flow. We follow Bookout Jr et al. (5) to model each grid in the 
dermis as a homogeneous volume, and the solute in blood circulation has a uniform concentration. 
Based on these assumptions, within each dermis grid, the solute convection of the capillary into the grid 
is given by       , where      is the blood flow into the dermis grid i and    is the solute concentration 
in the blood. When the capillary flow leaves the dermis grid, the capillary concentration is assumed to 
be in equilibrium with the concentration in the dermis grid, and thus the solute flux taken away by the 
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capillary is given by           , where     is the partition coefficient from dermis to blood. Therefore, 
for a dermis grid i, the mass balance equation is 
   
   
  
  ∑   
 
     (   
  
   
) (3) 
The above equilibrium assumption can be viewed as a simplification of the capillary clearance models 
reported in (18, 19), in which transient equations were used to model the permeation of solute from 
dermis into capillary. The transient equations are more complex since the permeability between dermis 
and capillary needs to be considered, in addition to the partition coefficient. 
The volumetric blood flow,     , can be estimated according to physiology. It is known that the 
average resting cardiac output is ca. 5.6 L min
-1
 for a human male and 4.9 L min
-1
 for a female (24), and 
the overall blood flow to skin is estimated to be 5% of cardiac output (5). Therefore, the overall skin 
blood flow can be estimated (              L min-1 for male and                L min-1). 
The blood flow is assumed to be distributed uniformly in the dermis; therefore the flow in each dermis 
grid (    ) can be calculated based on the volume of the grid and the volume of the dermis. We used the 
average skin surface area (1.8 m
2
) and typical dermis thickness of 1.2 mm (15) to calculate the volume 
of the dermis, therefore the model represents the absorption kinetics of a typical person. 
The systemic circulation and clearance is descried by the following equation: 
   
   
  
  ∑    (
  
   
   )
 
     (4) 
where    is the volume of whole-body blood vessel, and     is the first-order clearance that may 
include transport into other tissues and metabolism. The summation is with respect to all dermis grids, 
and  is the ratio of actual topical application area and the area being simulated. For computational 
efficiency, the lateral length being simulated usually covers a few corneocytes (one corneocyte in this 
study), and thus the simulated area is much smaller than the actual application area. The whole-body 
blood volume,   , can be calculated from the typical fraction of blood mass to that of adult body weight 
(7%) and the blood density (1.06 of water density). The clearance rate,  , of many pharmaceutically or 
toxicologically important chemicals is available from clinical pharmacokinetic studies of oral and/or 
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intravenous delivery routes. 
The simulation was performed by solving the ODEs on the grids explained above. All initial 
concentration is set to zero, except that in the vehicle. The left and right boundaries in the stratum 
corneum are periodic conditions, to represent a large application area. 
The model was implemented in C++, where the differential equations are solved by calling the 
state-of-the-art CVODE solver as part of the SUNDIALS computational package (25) developed in the 
Lawrence Livermore National Laboratory (computation.llnl.gov/casc/sundials). The user interface was 
written in Python (www.python.org) with extensive use of Scipy (a scientific module of Python, 
www.scipy.org). Interfacing between C++ and Python was achieved by using the SWIG (Simplified 
Wrapper and Interface Generator, www.swig.org) tool. The hybrid programming method was useful to 
achieve sufficient computational efficiency when solving a large number (3,190) of differential 
equations, whilst limiting the developmental time. The source code is publicly available at 
www.github.com/anthonytchen/lck. All computation was conducted on a laptop computer with dualcore 
CPU (2.80 GHz) installed with an Ubuntu (version 15.04) Linux operating system. 
 
Diffusion and partition coefficients of skin and vehicle 
The diffusion and partition coefficients of skin and vehicle depend on the physicochemical properties of 
the solute, including the molecular weight (MW, Da), the hydrophobicity in terms of octanol/water 
partition coefficient (   ), the dissociation constant (pKa), as well as the composition of the skin. A 
range of QSPR models have been reported for calculating the diffusion and partition parameters. In this 
section, the QSPR methods implemented in our model is outlined for completeness. More details can be 
found in the original articles (13, 15, 26). 
In the vehicle, the diffusion and partition coefficients depend on the formulation. If a simple 
aqueous solution is used, the partition coefficient between vehicle and water,    , is unity, and the 
diffusion coefficient can be calculated using the Stokes-Einstein equation: 
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 (5) 
where K is the Boltzmann constant, T is the temperature,   is the viscosity of water and    is the solute 
radius (Å) calculated as:    √            
 
 (27). 
In the stratum corneum, the partition coefficient between the “mortar” (the lipid bilayer) and water 
is determined by the following relationship: 
     
  
  
   
     (6) 
where    and     are the bulk density of lipid and water, respectively. The solute diffusion coefficient, 
  (m
2
 s
-1
) in the lipid is related to solute radius as described in (1, 13): 
    {
                  
           
                                                      
 (7) 
The partition coefficient between corneocytes (i.e. the “brick”) and water (   ) is estimated from the 
volume fraction of water in corneocytes (   is the fraction at saturation and    is the actual fraction), 
and the solute binding constant to keratin in stratum corneum (   ): 
                  (8) 
where                  
     and    is the bulk density of keratin (28, 29). The diffusion 
coefficient in the corneocyte (  ) is estimated according to the following equation of hindered diffusion 
(13): 
    
   (    )
  
  
√  
 
  
 
  
    (9) 
where      
       
 ,         [          ]
 
, and     is the radius of keratin microfibril (35 
Å). The others are parameters fitted to experimental data:       ,        ,       ,        
    . 
The partition coefficient (   ) in the viable epidermis and dermis is assumed to be the same, and 
so is the diffusion coefficient (  , m
2
 s
-1
), because of the similar multiphase compositions in the two 
skin layers (20, 30). This approach was also used in other modelling studies (15, 30, 31). We follow the 
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method presented in (15, 20) to relate the partition and diffusion coefficients to solute ionisation and 
binding to albumin as follows: 
         (     
    
  
              ) (10) 
    
                  
     
    
  
              
 (11) 
where      is the non-ionised fraction of solute in the aqueous phase;      depends on the chemical 
dissociation constant and the pH of the solution, and it can be calculated by using the formulate given in 
(32, p.72) or more sophisticated software tools (e.g. ACD/Labs). The fraction of unbound (to albumin) 
solute (  ) may be estimated by using the QSPR model developed in (33). 
Finally, the dermis to blood partition coefficient,    , needs to be estimated. In the literature, 
various QSPR models have been reported for volatile organic compounds, where     can be related to 
experimentally measured oil-to-air and/or saline-to-air partition coefficients (34). Alternatively it can 
also be estimated by using the Abraham descriptors and accordingly the QSPR model reported in (26).  
 
Model Demonstration: Clinical Studies of Nicotine  
A published clinical study of transdermal delivery of nicotine (23) was used to support model 
development and demonstration. The model was also applied to predict another clinical study of 
nicotine (44), which was not considered during model development, to test the prediction performance. 
Nicotine replacement therapy has been widely used for the purpose of smoking cessation, and its 
transdermal delivery has been popular. One important advantage of the transdermal route is that it 
provides continuous and controlled release of the drug, which has contributed to the reduction of 
craving and withdrawal symptoms during smoking cessation. As a result, various nicotine transdermal 
systems have been developed, with many clinical studies reported in the literature (e.g., 23, 35). A brief 
description of the study by Bannon et al. (23), which was used to support model development, is given 
below. 
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Bannon et al. (23) investigated the absorption of nicotine delivered from a hydrogel based matrix-
type transdermal patch (Nicolan
TM
). Three dose levels were studied by varying the surface areas of the 
patch: 3.5 cm
2
 for 15 mg, 7.0 cm
2
 for 30 mg, and 14.0 cm
2
 for 60 mg. Healthy smokers were recruited 
for the study, and they agreed to abstain from smoking prior to and during the study which was verified 
by monitoring the carbon monoxide levels. In the first study, the transdermal patches were applied to 
the volar forearm of nine subjects for 24 hrs and the plasma nicotine concentration was measured at 
several time points up to 30 hrs. The aim was to examine the impact of dose level on absorption kinetics. 
In the multiple dose study, the subjects were given one fresh 30-mg patch every 24 hrs for seven days 
and blood samples were taken at various time points. The total delivered dose was approximately 85% 
of the nicotine content in the patches, as calculated from measuring the residual nicotine in the patch 
after removal. 
To simulate the above scenarios, various skin physiology and solute physicochemical parameters 
are needed; these were largely taken from the literature and summarised in Table 1. We adjusted the 
number of cell layers in the stratum corneum according to the reported thickness at volar forearm, 
which has significant variability within one study and between different studies. The thickness of the 
stratum corneum was set to 20.5  m, which is the average measured by Egawa et al. (36) (22.6  m) and 
Sandby-Moller et al. (37) (18.3  m). This thickness corresponds to 23 corneocyte-lipid layers 
(assuming 0.875  m for each layer (15)). The thickness of the patch was not given; hence the nicotine 
concentration in the vehicle has to be estimated. We followed similar modelling studies (e.g. 22) to 
assume a vehicle depth of 100  m, from which and the given surface area the concentration can be 
determined.  
The partition and diffusion coefficients of nicotine in the hydrogel-based vehicle depend on the 
properties of the hydrogel. Solute partitioning and diffusion in hydrogel has been widely studied both 
theoretically and experimentally (38, 39). Hydrodynamic hindrance of hydrogel on the diffusion 
coefficient is rather limited for small molecules, often less than 10% reduction of that in water (38, 40). 
For this reason, the diffusion coefficient of nicotine in the hydrogel vehicle was fixed to the same value 
as in water (calculated in eq. (5)). The partition coefficient between hydrogel and water was typically 
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reported to be between 0.5 and 1, depending on the volume fraction of dispersed polymers (39). In this 
study, the partition coefficient of nicotine between vehicle and water was set to 0.7. Due to the lack of 
precise information about the vehicle, sensitivity analysis was conducted to investigate the impact of 
vehicle properties (partition and diffusion coefficients). 
 
Table 1. The input parameters of the model for simulating the nicotine study.  
Part name Parameter Value 
Nicotine Molecular weight (MW) 162.23 Da 
 Octanol-water partition coefficient (log   ) 1.17 
 Fraction of non-ionised solute (    ) 0.31 
 Fraction of unbound solute (  ) 0.95 
Vehicle Thickness 100  m 
 Initial nicotine concentration 428.57 mg mL
-1
 
Stratum corneum Number of corneocyte layers 23 (volar forearm) 
 Width of corneocytes 40  m 
 Height of corneocytes 0.8  m 
 Thickness of inter-cellular lipid 0.075  m 
 The lateral spacing between corneocytes 0.075  m 
Viable epidermis Thickness 100  m 
Dermis Thickness 1200  m 
 Dermis-blood partition coefficient of nicotine (log   ) -0.04 
Blood Cardiac output 5.6 L min
-1
 
 Skin blood flow as fraction of cardiac output 5% 
 Nicotine clearance in blood ( ) 1.40 L min-1 
 
The diffusion and partition properties of nicotine in stratum corneum were calculated in the same 
way as previously verified (14). The fraction of nonionised nicotine at pH 7.4 and binding to plasma 
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protein, which are needed for these calculations, were set to the experimentally reported values: 
          and         (41, 42). The partition coefficient of nicotine between dermis and blood is 
also set to the experimental value:              (26). The nicotine clearance in systemic circulation 
was set to 1.40 L min
-1
 as reported (42). 
The other clinical study reported the systemic kinetics of the Nicorette
®
 Invisi 25 mg Patch
TM
 
(McNeil Products Ltd., Maidenhead, UK) (44). The patch was designed to be worn for 16 hrs and 
plasma concentration data were available for 32 hrs. The vehicle concentration was calculated based on 
the reported loading dose (1.75 mg/cm
2
), patch size (22.5 cm
2
) and the assumed vehicle thickness of 
100  m. All other input parameters are the same as the Nicolan case described above. The intention was 
to further test the prediction performance of the model. 
 
RESULTS  
For the Nicolan patch, the predicted plasma concentration for different dose levels is illustrated in 
Figure 2, in comparison with the clinical data. It appears that the model is capable of reproducing the 
main trend of the kinetics in plasma. This is especially the case for the intermediate dose level of 30 mg. 
For 60 mg, the model slightly over-predicts the rate of increase in concentration at the beginning, whilst 
for 15 mg, the peak concentration is slightly over-predicted. It should be noted that in the original report 
(23), only the mean concentration values of nine subjects were given but not the standard deviation, and 
thus it is not possible to fully consider the inter-subject variability in comparison. However, for 30 mg, 
the data from both the single dose study and the first 24 hrs of the multiple dose study were augmented 
in Figure 2, and even these two sets of average data exhibit significant differences. Therefore, the 
difference between the model prediction and clinical data is well within the variability of such clinical 
studies. 
 (Figure 2 about here) 
Table 2 compares the predicted pharmacokinetic parameters for the single dose study with the 
experimentally derived data. As observed from Figure 2, the model tends to predict the time to reach 
15 
 
maximum concentration (tmax) earlier than that indicated by the data, though still within 1.0~1.5 
standard deviation from the average of the data. The prediction of the remaining pharmacokinetic 
parameters, such as AUCs, Cmax and the fraction of absorbed dose (f), is in good agreement with the 
data. 
 
Table 2. Plasma nicotine pharmacokinetic parameters for the single dose study. Standard deviation is 
given in the parentheses. In the clinical study, the fraction of solute absorbed (f) was calculated from 
residual nicotine in the patch after removal. 
Dose level 15 mg 
Data 
 
Model 
30 mg 
Data 
 
Model 
60 mg 
Data 
 
Model 
AUC0-30   
(ng hr mL
-1
) 152 (34.6) 153 294 (53.1) 273 509 (88.9) 494 
AUCinf     
(ng hr mL
-1
) 170 (36.5) 165 310 (56.4) 294 541 (99.7) 533 
tmax (hr) 7.78 (4.27) 5.53 7.78 (1.86) 5.53 8.22 (3.07) 5.53 
Cmax         
(ng mL
-1
) 8.02 (1.96) 8.62 17.1 (5.03) 15.4 28.9 (9.14) 27.9 
f 0.85 (0.084) 0.82 0.87 (0.024) 0.82 0.83 (0.072) 0.82 
 
Figure 3 compares the model prediction and clinical data for the 30 mg multiple dose study. 
Apparently the predicted end-of-day plasma concentration, when the old patch is replaced by a new one, 
is higher than the actual data. In the collected data, the value at 24 hrs for the multiple dose study (4.58 
ng mL
-1
) was also reported to be substantially lower than the value for the single dose study (7.90 ng 
mL
-1
). Therefore the model prediction is in reasonably good agreement with the data. Another 
observation is that from day 2, the model predicted plasma concentration cycles quite stably with 
negligible day-to-day variation, whereas the reported clinical data showed variation at 24, 48, 96, 144 
and 168 hrs. 
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(Figure 3 about here) 
Figure 4 illustrates the simulated disposition of nicotine at different skin layers, in the blood 
compartment and the cumulative amount cleared from the blood. The simulation was extended to 50 hrs 
(i.e. 26 hrs after the patch is removed) to allow for sufficient clearance of nicotine from the system. It 
can be seen that within the skin, the majority of the applied dose is absorbed in the stratum corneum, 
whilst the viable epidermis and dermis contain very small proportions. The concentration of nicotine in 
the stratum corneum is significantly higher than that in the underlying viable epidermis and dermis. 
There is a large partition coefficient of nicotine between the stratum corneum (lipid) to viable epidermis 
(K=7.73).  The diffusion of nicotine in the viable epidermis and dermis (           m2 s-1) is also 
much faster than that in lipid bilayer (           m2 s-1) and corneocyte (           m2 s-1) in the 
stratum corneum. Physiologically, the viable epidermis and dermis contain up to 70% aqueous phase 
(20), which has important impact on the partition and diffusion coefficients of the lipophilic nicotine. In 
addition, the concentration of solute in systemic circulation also appears to be much lower than in the 
stratum corneum, which is likely due to the rapid clearance as a result of metabolism into cotinine (23). 
The detailed modelling of various plasma clearance pathways, e.g. metabolism and transport into other 
tissues, is outside the scope of this study. 
(Figure 4 about here) 
From the simulation results, the relative ratio of nicotine deposition in skin can be obtained. Figure 
5 gives the relative percentage nicotine disposition within the stratum corneum; it shows that more 
solute stays in the corneocyte (the “brick”) than in the lipid (the “mortar”). Although the concentration 
in the lipid is much higher than that in the corneocyte (c.f. Figure 6), the total volume fraction of lipid in 
the stratum corneum is only about 8.7% (calculated by using the geometric parameters in Table 1), and 
thus the total solute amount in lipid is less. In addition, the peak amount in the lipid is achieved more 
quickly than in the corneocyte; this is expected because the diffusion coefficient in the lipid is much 
higher than that in the corneocyte. 
(Figure 5 about here) 
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Figure 6 gives detailed disposition of nicotine in the stratum corneum at different time points using 
two-dimensional concentration surface plots. The profiles vividly illustrate the dominant role of lipid 
pathway in skin penetration for this lipophilic compound, though the effect of corneocyte is not 
negligible. At the early stage of permeation, the diffusion along the lipid creates a clear “fingering” 
effect as seen in the figure. It is also interesting to observe that at the beginning, when solute diffuses 
along the lipid layer, it may “back-diffuse” from a lower lipid layer to upper corneocytes due to the 
gradient in chemical potential (considering gradient in concentration and the effect of partitioning). This 
back-diffusion may slow down the initial penetration rate as corneocytes serve as “reservoirs” and need 
to be filled with the solute from the lipid. In a later stage, these reservoirs first reach equilibrium with 
surrounding lipid and then release the solute as the chemical potential in the lipid is further lowered due 
to diffusion into the dermis and viable dermis.  This corresponds to the point when a significant amount 
of solute has been consumed in the patch. Release from corneocyte reservoirs can be clearly seen when 
the patch is removed (i.e. after 24 hrs). For example in Figure 6(e)(f), the concentration in the centre of 
the topmost corneocyte layer is even higher than that in the surrounding lipid layer, and when combined 
with the effect of partitioning the chemical potential gradient creates significant driving force to release 
the solute.  
(Figure 6 about here) 
Figure 7 shows the sensitivity analysis with respect to the model input parameters in the vehicle of 
the Nicolan study. We first examine the likely effect of varying the partition coefficient between vehicle 
and water from 1/10 to 10 times of its nominal value (       ). Increasing the partition coefficient 
represents the use of a more hydrophobic vehicle formulation. Conversely, decreasing the partition 
coefficient mimics the use of a more hydrophilic formulation. Clearly, changing vehicle partition 
property has a significant impact on the delivered plasma concentration (Figure 7(a)). Using a more 
hydrophilic vehicle of lower partition coefficient results in faster increase of plasma concentration, 
shorter tmax, and higher Cmax of nicotine. The plasma concentration of nicotine at later stage is also more 
rapidly depleted. In contrast, by using a more hydrophobic vehicle of higher partition coefficient, 
nicotine is predicted to favour staying in the vehicle, leading to sustained slower release into skin and 
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blood circulation. For a given vehicle formulation, different solutes also have different vehicle:water 
partition coefficients but the effect is more complicated, as the partition and diffusion properties in the 
skin will also vary.  
(Figure 7 about here) 
We also examine the effect of nicotine mobility in the vehicle. The diffusion coefficient of nicotine 
in vehicle was reduced to 1/10, 1/100, 1/1000 and 1/10000. This essentially models the effect of 
controlled releases. Figure 7(b) shows that reducing the diffusion coefficient of the vehicle by two 
orders of magnitude has negligible impact on the pharmacokinetics of nicotine delivery – its plasma 
concentration appears to be not distinguishable. The diffusivity of nicotine in vehicle only starts to 
reduce the plasma concentration when this parameter is reduced by more than 100-fold. Further 
reduction of the diffusion in vehicle makes this parameter comparable with that in skin, and thus it 
slows down the penetration, leading to sustained slow release and lower plasma concentration. 
Finally, Figure 8 illustrates the results for the separate Nicorette data set reported by DeVeaugh-
Geiss et al (44). Good agreement between model prediction and clinical data is also achieved. The 
predicted kinetics is appreciably faster than the actual data (experimentally derived tmax is 12.0 hrs, 
while the prediction gives 6.0 hrs). Nevertheless, the model was able to describe the main pattern of the 
profile, with good prediction of AUC0-32 (model: 262.9 ng hr mL
-1
; data: 238.51 ng hr mL
-1
) and Cmax 
(model: 14.50 ng mL
-1
; data: 16.56 ng mL
-1
). 
(Figure 8 about here) 
DISCUSSIONS 
The primary intention of this paper is to present an integrated mechanistic model that captures the 
important molecular and microscopic principles involved in skin penetration and systemic 
bioavailability. To demonstrate the use of the integrative mechanistic model, two sets of published 
clinical data of nicotine patches (23, 44) have been simulated. The predicted nicotine concentration in 
systemic circulation is in good agreement with the reported clinical data. Furthermore, after validation 
with plasma concentration, such a bottom-up model can predict the microscopic kinetic and 
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bioavailability information in various skin layers, which may not be easily measured in clinical studies 
but are of particular importance for intended topical delivery. From the simulation, the disposition of 
nicotine in different skin layers is also obtained (Figures 4-6).  
In the simulation, all input parameters for the vehicle, stratum corneum, viable dermis, dermis and 
systemic circulation were derived separately from their molecular, microscopic and physiology bases. 
The nicotine partition and diffusion coefficients in the hydrogel-based vehicle were estimated by 
referring to “typical” hydrogel properties and the impact on solute diffusion/partition reported in the 
literature (38, 39). Reducing the diffusion coefficient in vehicle within 3 orders of magnitude was found 
to have negligible impact on the simulation results. The partition coefficient between vehicle and water 
however does have a significant effect.  The chosen value (0.7) was derived by mainly considering the 
exclusion effect. Mathematically, vehicle partition coefficient can be further refined by optimisation so 
that the fit to the clinical data could be further improved. Nevertheless, that vehicle partition coefficient 
has significant effect on the simulation results, as shown in the sensitivity analysis, is a valuable insight 
for controlling the delivery of topically applied nicotine. Experimental and theoretical insight for 
designing vehicle partition property is an area of active research (38, 39, 40). Here we performed a 
systematic sensitivity analysis of the vehicle. Increasing the hydrophobicity of the vehicle leads to 
slower release and sustained delivery of nicotine to systemic circulation. Using more hydrophilic 
vehicle formulation leads to faster delivery depletion of nicotine in the plasma circulation. Reducing the 
diffusion coefficient of the vehicle by 3 orders of magnitude has negligible effect on the 
pharmacokinetics of nicotine release, absorption and bioavailability. For controlled release formulations 
to be effective, the equivalent diffusion coefficient of nicotine in the vehicle has to be reduced by more 
than two orders of magnitude.    
In the clinical studies only the area of the patch is given, but not the depth. For the simulation, the 
thickness of the vehicle is estimated from the dose. Varying the depth of the vehicle requires the 
corresponding adjustment of nicotine concentration and hence can impact on pharmacokinetics of 
plasma concentration of nicotine but the shape of curve will remain. This feature enabled us to estimate 
the thickness of the vehicle to be ca. 100  m. The corresponding initial nicotine concentration in the 
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vehicle (Nicolan) is 428.57 mg mL
-1
, or 42.67% w/w, (assuming the vehicle as an ideal aqueous 
solution). This value is close to the nicotine concentration (48% w/w) achieved for the maximum 
steady-state flux across skin (43).  
 
CONCLUSION 
This paper reports the development of a detailed mechanistic model that integrates the skin penetration 
model with systemic circulation kinetics. To validate the model, the published clinical data of 
transdermal pharmacokinetics of nicotine was simulated. All input parameters for the model, including 
the solute (nicotine), the vehicle, the stratum corneum, the dermis, the viable dermis and systemic 
circulation, were determined independent of the in vivo pharmacokinetics being predicted. The 
integrated mechanistic modelling has significantly extended the applicability of the current microscopic 
skin penetration model by providing prediction of solute concentration in the blood. In addition, by 
using advanced computational techniques, we report the simulation of detailed two-dimensional 
concentration profile in the stratum corneum, which provides useful information of the local sub-
cellular disposition kinetics in skin. The future work will be focused on more comprehensive validation 
of the model with a wide range of chemicals, and further assessment of the usability of this model in the 
design and safety assessment of pharmaceutical, personal care and other chemical products to which the 
transdermal route is relevant.  
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Legend to Figures 
 
 
Figure 1. Overview of the modelling framework. 
 
Figure 2. Comparison of modelling results with the published clinical data of Bannon et al. (23) 
following the application of nicotine transdermal patches with different doses (patch removed after 24 
hrs of application). 
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Figure 3. Comparison of modelling results with clinical data of Bannon et al. (23) following the 
application of nicotine transdermal patches that were replaced every 24 hrs. 
 
Figure 4. Simulated disposition of nicotine in different skin layers and the circulation. The patch is 
removed after 24 hrs of application.  
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Figure 5. Simulated disposition of nicotine in lipid and corneocytes, and their relative amount 
(percentage) with respect to the total nicotine in the stratum corneum. The initial dose in the vehicle is 
30 mg, and the patch is removed after 24 hrs of application.  
 
 
(a)                                          (b) 
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(c)                                          (d) 
 
(e)                                          (f) 
 
Figure 6. Microscopic disposition of nicotine in the stratum corneum. The initial dose in the vehicle is 
30 mg, and the patch is removed after 24 hrs of application. The unit in all colour maps is mg mL-1. 
The boundary between lipid and corneocytes are marked with solid line. Note that because of the very 
small lipid size relative to that of corneocytes, the 2D simulation domain is illustrated in terms of grid 
points and thus is not to scale. (a) 0.5 hr; (b) 1 hrs; (c) 2 hrs (d) 24 hrs; (e) 25 hrs; (f) 25 hrs with 
adjusted colour map. The same, fixed colour map was used for (a)-(e), but to illustrate the detailed 
concentration profile at 25 hrs, the colour map in (e) was adjusted to produce (f). 
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Figure 7. Sensitivity analysis of the impact of vehicle properties on systemic kinetics of nicotine. (a) 
The impact of vehicle:water partition coefficient; (b) The impact of diffusion coefficient in vehicle. The 
legend “    ” denotes that the input parameter in the base model was multiplied by 0.1 to obtain the 
result. Experimental data is from Bannon et al. (23). 
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Figure 8. Comparison of model prediction with the published clinical data of Nicorette patch from 
DeVeaugh-Geiss et al. (44). 
 
